http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
-
Day One Biopharmaceuticals (DAWN) Announces Updated FIREFLY-1 Data for Tovorafenib
-
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
-
Day One Biopharmaceuticals (DAWN) Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
-
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
-
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
-
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
-
Day One (DAWN) Announces New FIREFLY-1 Data for Tovorafenib and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
-
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
-
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
-
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
-
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
-
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
-
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
-
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
-
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
-
Day One to Participate in the Cowen 43rd Annual Health Care Conference
-
Day One to Participate in the Cowen 43rd Annual Health Care Conference
-
Day One Biopharmaceuticals (DAWN) Reports Strong Topline Data from Pivotal Phase 2 FIREFLY-1 Trial
-
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
-
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
-
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
-
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
-
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
-
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
-
Day One Biopharmaceuticals (DAWN) Enters Research and Development Agreement with National Cancer Institute for Development of Tovorafenib
-
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
-
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
-
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care
-
Day One Biopharmaceuticals (DAWN) Appoints Garry Nicholson as Chairman of the Board of Directors
-
Day One Appoints Garry Nicholson as Chairman of the Board of Directors
-
Day One Appoints Garry Nicholson as Chairman of the Board of Directors
-
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress
-
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress
-
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
-
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
-
Day One Biopharmaceuticals (DAWN) Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
-
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
-
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
-
Day One (DAWN) Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
-
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
-
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
